vs

Side-by-side financial comparison of Esperion Therapeutics, Inc. (ESPR) and MP Materials Corp. (MP). Click either name above to swap in a different company.

Esperion Therapeutics, Inc. is the larger business by last-quarter revenue ($168.4M vs $90.6M, roughly 1.9× MP Materials Corp.). On growth, Esperion Therapeutics, Inc. posted the faster year-over-year revenue change (143.7% vs 49.1%). Over the past eight quarters, MP Materials Corp.'s revenue compounded faster (70.3% CAGR vs 10.6%).

Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan.

MP Materials Corp. is a U.S.-based producer of rare earth materials. The company owns and operates the Mountain Pass mine in California, the only active rare earth mining and processing facility in the Western Hemisphere, producing essential materials for electric vehicles, wind turbines, and defense applications.

ESPR vs MP — Head-to-Head

Bigger by revenue
ESPR
ESPR
1.9× larger
ESPR
$168.4M
$90.6M
MP
Growing faster (revenue YoY)
ESPR
ESPR
+94.7% gap
ESPR
143.7%
49.1%
MP
Faster 2-yr revenue CAGR
MP
MP
Annualised
MP
70.3%
10.6%
ESPR

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
ESPR
ESPR
MP
MP
Revenue
$168.4M
$90.6M
Net Profit
$-8.0M
Gross Margin
Operating Margin
50.6%
Net Margin
-8.8%
Revenue YoY
143.7%
49.1%
Net Profit YoY
64.8%
EPS (diluted)
$0.32
$-0.04

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ESPR
ESPR
MP
MP
Q1 26
$90.6M
Q4 25
$168.4M
$52.7M
Q3 25
$87.3M
$53.6M
Q2 25
$82.4M
$57.4M
Q1 25
$65.0M
$60.8M
Q4 24
$69.1M
$61.0M
Q3 24
$51.6M
$62.9M
Q2 24
$73.8M
$31.3M
Net Profit
ESPR
ESPR
MP
MP
Q1 26
$-8.0M
Q4 25
$9.4M
Q3 25
$-31.3M
$-41.8M
Q2 25
$-12.7M
$-30.9M
Q1 25
$-40.5M
$-22.6M
Q4 24
$-22.3M
Q3 24
$-29.5M
$-25.5M
Q2 24
$-61.9M
$-34.1M
Operating Margin
ESPR
ESPR
MP
MP
Q1 26
Q4 25
50.6%
-7.0%
Q3 25
-11.4%
-125.2%
Q2 25
8.6%
-76.5%
Q1 25
-34.0%
-57.2%
Q4 24
-6.4%
-72.1%
Q3 24
-31.0%
-62.8%
Q2 24
3.5%
-171.1%
Net Margin
ESPR
ESPR
MP
MP
Q1 26
-8.8%
Q4 25
17.9%
Q3 25
-35.9%
-78.0%
Q2 25
-15.4%
-53.8%
Q1 25
-62.2%
-37.2%
Q4 24
-36.6%
Q3 24
-57.2%
-40.5%
Q2 24
-83.9%
-108.9%
EPS (diluted)
ESPR
ESPR
MP
MP
Q1 26
$-0.04
Q4 25
$0.32
$0.07
Q3 25
$-0.16
$-0.24
Q2 25
$-0.06
$-0.19
Q1 25
$-0.21
$-0.14
Q4 24
$-0.14
$-0.12
Q3 24
$-0.15
$-0.16
Q2 24
$-0.33
$-0.21

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ESPR
ESPR
MP
MP
Cash + ST InvestmentsLiquidity on hand
$167.9M
$1.7B
Total DebtLower is stronger
$1.0B
Stockholders' EquityBook value
$-302.0M
$2.0B
Total Assets
$465.9M
$3.8B
Debt / EquityLower = less leverage
0.51×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ESPR
ESPR
MP
MP
Q1 26
$1.7B
Q4 25
$167.9M
$1.2B
Q3 25
$92.4M
$1.1B
Q2 25
$86.1M
$261.5M
Q1 25
$114.6M
$198.3M
Q4 24
$144.8M
$282.4M
Q3 24
$144.7M
$284.4M
Q2 24
$189.3M
$295.6M
Total Debt
ESPR
ESPR
MP
MP
Q1 26
$1.0B
Q4 25
$998.7M
Q3 25
$997.3M
Q2 25
$910.8M
Q1 25
$909.8M
Q4 24
$908.7M
Q3 24
Q2 24
Stockholders' Equity
ESPR
ESPR
MP
MP
Q1 26
$2.0B
Q4 25
$-302.0M
$2.0B
Q3 25
$-451.4M
$2.0B
Q2 25
$-433.5M
$1.0B
Q1 25
$-426.2M
$1.0B
Q4 24
$-388.7M
$1.1B
Q3 24
$-370.2M
$1.1B
Q2 24
$-344.2M
$1.1B
Total Assets
ESPR
ESPR
MP
MP
Q1 26
$3.8B
Q4 25
$465.9M
$3.9B
Q3 25
$364.0M
$3.8B
Q2 25
$347.1M
$2.3B
Q1 25
$324.0M
$2.4B
Q4 24
$343.8M
$2.3B
Q3 24
$314.1M
$2.3B
Q2 24
$352.3M
$2.4B
Debt / Equity
ESPR
ESPR
MP
MP
Q1 26
0.51×
Q4 25
0.50×
Q3 25
0.51×
Q2 25
0.90×
Q1 25
0.88×
Q4 24
0.86×
Q3 24
Q2 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ESPR
ESPR
MP
MP
Operating Cash FlowLast quarter
$45.2M
$-1.9M
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
0.0%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ESPR
ESPR
MP
MP
Q1 26
$-1.9M
Q4 25
$45.2M
$-46.9M
Q3 25
$-4.3M
$-42.0M
Q2 25
$-31.4M
$-3.7M
Q1 25
$-22.6M
$-63.2M
Q4 24
$-35.0M
$30.5M
Q3 24
$-35.3M
$-6.8M
Q2 24
$-7.2M
$30.8M
Free Cash Flow
ESPR
ESPR
MP
MP
Q1 26
Q4 25
$-109.3M
Q3 25
$-92.5M
Q2 25
$-32.7M
Q1 25
$-93.7M
Q4 24
$-11.2M
Q3 24
$-35.5M
$-53.3M
Q2 24
$-7.3M
$-15.6M
FCF Margin
ESPR
ESPR
MP
MP
Q1 26
Q4 25
-207.4%
Q3 25
-172.8%
Q2 25
-56.9%
Q1 25
-154.0%
Q4 24
-18.3%
Q3 24
-68.7%
-84.7%
Q2 24
-9.9%
-50.1%
Capex Intensity
ESPR
ESPR
MP
MP
Q1 26
Q4 25
0.0%
118.5%
Q3 25
0.0%
94.3%
Q2 25
0.0%
50.5%
Q1 25
0.0%
50.1%
Q4 24
0.0%
68.3%
Q3 24
0.3%
73.8%
Q2 24
0.1%
148.7%
Cash Conversion
ESPR
ESPR
MP
MP
Q1 26
Q4 25
-4.97×
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ESPR
ESPR

Collaboration Revenue$124.7M74%
Products$43.7M26%

MP
MP

Materials Segment$72.2M80%
Magnetics Segment$21.1M23%

Related Comparisons